Dating chat venn
We estimate that the Sedana contract announced in November 2016 and the €5.7m contracts won in January and February this year will contribute €4.3m in fee income in the current year.The Company has a strong proposal book, which should begin to turn in to business wins now that the full R&D lifecycle proposition is up and running.The shares of Venn have slid by 11% over the past 3 months, and given this trading update and its potential to meet expectations for full-year results, it presents a potential buying opportunity for investors.Delivery of our 2017 forecasts should see a recovery in the share rating and we see scope for the shares to surpass 30p over that horizon which would put the shares on a 16.5x 2018 earnings rating.In a small-cap like this, one or two larger sellers can easily drive the share price down to silly levels given the propensity of others to follow them out on a drifting share price, the hitting of stop-losses etc. As spooky says, it looks like the share price has hit a bottom and is starting to lift itself off that bottom now.The solid H1 update and the confidence for the full year should continue this into and onwards from the H1 results next month.rivaldo: Hybridan brought out a new note on Thursday envisaging a 30p share price on delivery of 2017 forecasts.Venn Life Sciences Holdings Plc has a 4 week average price of 0p and a 12 week average price of 4p.
The sector continues to see growth, with encouraging trends in outsourcing likely to continue.
Their forecasts are: this year : €1.83 EPS, €3.62m cash pile next year : €2.07 EPS, €4.03m cash pile "Solid H1 2017 After a lacklustre full year results released in March 2017, the growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceuticals, biotechnology and medical device clients today provided a trading update for the six months ended 30 June 2017.
The new financial year started well with the Company securing contract wins in January and February with a value of €5.7m.
On a PSR basis, this would value VENN at around €22.5m. PSR are a far smaller CRO & goes to show the lowly valuation VENN are currently on.
On an EBITDA basis this would value VENN at around €15m. I've been picking up stock recently - & some more today - as I envisage that Private Equity or competitor may soon cast their eyes in this direction & determine that they could offer a decent premium & still acquire VENN on a fairly low multiple of turnover or EBITDA.